CN113648272B

CN113648272B - Moisturizing and wrinkle-removing eye cream and preparation method thereof

Info

Publication number: CN113648272B
Application number: CN202110988692.5A
Authority: CN
Inventors: 林俊生; 林静静
Original assignee: Junctional Pacific Ltd; Huaqiao University
Current assignee: Junctional Pacific Ltd; Huaqiao University
Priority date: 2021-08-26
Filing date: 2021-08-26
Publication date: 2022-05-27
Anticipated expiration: 2041-08-26
Also published as: CN113648272A

Abstract

The invention discloses a moisturizing and wrinkle-removing eye cream which is prepared from the following components in parts by weight: the components for conditioning the skin are monarch: new Zealand vanilla extract, coffee extract, hydrolyzed soybean polypeptide, heparin sodium, L-histidine, allantoin, recombinant human fibroblast 8a, caprylic/capric triglyceride, hexyldecanol, bisabolol, cetyl N-palmitoyl hydroxyproline, campesterol, nicotinamide; the components for moisturizing and crease-proofing are as the ministers: white chinlon oil, acetylated sodium hyaluronate, glycerol, sodium polyglutamate, dipeptide diaminobutyryl benzylamide diacetate, butanediol, acetyl hexapeptide-8 and squalane; the long-acting antioxidant component is adjuvant: p-hydroxyacetophenone; the cyclodextrin is matched to play a role of slow release and long acting, and the components of emulsification, fragrance fixation, sedation, relaxation and the like are used as the active ingredients. The moisturizing and wrinkle-removing eye cream can effectively repair skin around eyes and remove fine wrinkles and dry wrinkles around the eyes, and is safe, mild and non-irritant in the formula. The invention also discloses a preparation method of the moisturizing and wrinkle-removing eye cream.

Description

Moisturizing and wrinkle-removing eye cream and preparation method thereof

Technical Field

The invention relates to the technical field of cosmetics, in particular to moisturizing and wrinkle-removing eye cream and a preparation method thereof.

Background

The skin around the eyes is the thinnest and fragile place in the human body and the place which is easy to age, wrinkles are easy to grow, special care is needed, or problems such as bags, wrinkles, canthus drooping, dark circles and the like are easy to appear, so that more and more people pay attention to the care of the skin around the eyes, and the use of eye cream is necessary.

The existing eye cream has various varieties, and most of the components are chemically synthesized, and some of the components are easy to cause skin discomfort and even cause anaphylactic reaction; some cosmetics contain natural substances, but have single effect, lack of overall conditioning, have unobvious effects of removing wrinkles and moisturizing, and cannot fundamentally improve the texture of skin around eyes. These cosmetics are not suitable for long-term use.

Disclosure of Invention

The invention aims to provide the moisturizing and wrinkle-removing eye cream which can effectively repair skin around eyes and remove fine wrinkles and dry wrinkles around the eyes, and is safe, mild and non-irritant in a formula.

The invention also aims to provide a preparation method of the moisturizing and wrinkle-removing eye cream.

In order to achieve the above purpose, the solution of the invention is:

the moisturizing and wrinkle-removing eye cream comprises the following raw materials in parts by weight:

an agent A: 0.04-0.05 part of disodium hydrogen phosphate, 0.35-0.36 part of sodium dihydrogen phosphate, 0.015-0.03 part of EDTA disodium, 0.165-0.175 part of tromethamine and 57.3-57.4 parts of deionized water;

and (2) agent B: 2.95-3.05 parts of caprylic/capric triglyceride, 0.15-0.25 part of cetyl N-palmitoyl hydroxyproline, 0.15-0.25 part of rape sterol, 0.15-0.25 part of hexyldecanol, 0.15-0.25 part of bisabolol, 0.15-0.25 part of stearic acid, 2.95-3.05 parts of meadowfoam seed oil, 0.15-0.25 part of cyclopentadimethylsiloxane, 0.75-0.85 part of sucrose polystearate, 0.75-0.85 part of hydrogenated polyisobutene, 0.2-0.3 part of glyceryl stearate, 0.15-0.25 part of polydimethylsiloxane cross-linked polymer, 4.95-5.05 parts of squalane, and 0.55-0.65 part of acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer;

c, agent C: 0.0001-0.0002 part of a New Zealand vanilla extract, 0.95-1.05 part of a coffee extract, 0.15-0.25 part of acetylated sodium hyaluronate, 0.15-0.25 part of sodium polyglutamate, 0.95-1.05 part of cyclodextrin and 0.35-0.45 part of hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer;

and (3) agent D: 1.45-1.55 parts of glycerol, 0.0001 part of heparin sodium, 0.5-0.6 part of L-histidine, 0.45-0.55 part of allantoin, 0.0000001-0.0000002 part of recombinant human fibroblast 8a (rhFGF8a), 4.95-5.05 parts of hydrolyzed soybean polypeptide, 0.95-1.05 part of nicotinamide, 1.35-1.45 parts of glycerol stearate citrate, 89.95-10.05 parts of acetyl hexapeptide, 0.45-0.55 part of dipeptide diaminobutyrylbenzyl amide diacetate, 0.35-0.45 part of p-hydroxyacetophenone, 0.2-0.3 part of phenoxyethanol, 0.2-0.3 part of ethylhexylglycerol, 0.2-0.3 part of PEG-100 stearate, 0.75-0.85 part of cetearyl alcohol and 1.95-2.05 parts of butanediol.

A preparation method of the moisturizing and wrinkle-removing eye cream comprises the following steps:

step 1, adding the components of the agent A into a first mixing tank according to a formula proportion, stirring and dissolving at room temperature, and adjusting the pH value to 5.5-6.5 by using citric acid-sodium citrate;

step 2, adding the components of the agent B into a second mixing tank according to the formula proportion, heating to 80-90 ℃ under stirring, and keeping for 15-25 min;

step 3, adding the components of the agent C into a third mixing tank according to the formula proportion, then adding 6.25-6.35 parts of the agent A dissolved in the step 1, and heating to 60-65 ℃ under stirring;

step 4, adding the mixture of the agent A and the agent C formed in the step 3 into a second mixing tank to form a mixture of the agent A, the agent C and the agent B, continuously stirring and cooling to 60-65 ℃, and keeping for 15-25 min;

step 5, adding the components of the agent D into a fourth mixing tank according to the formula proportion, adding 51.0-51.1 parts of the agent A dissolved in the step 1, and heating to 40-45 ℃ under stirring;

step 6, pumping the mixture of the agent A, the agent C and the agent B at the temperature of 60-65 ℃ in the step 4 into a homogenizer, homogenizing for 5-25 min at 3600-8000 rpm, pumping out, adding into a fourth mixing tank in a stirring state, mixing with the mixture of the agent A and the agent D, and continuously stirring for 5-25 min at the temperature of 40-45 ℃;

and 7, finally, pumping all the mixture in the fourth mixing tank at the temperature of 40-45 ℃ in the step 6 into a homogenizer, homogenizing at 3600-8000 rpm for 10-25 min, cooling to 35-38 ℃, aging for 24h, canning and subpackaging to obtain the moisturizing and wrinkle-removing eye cream.

After the technical scheme is adopted, the moisturizing and wrinkle-removing eye cream disclosed by the invention is prepared by screening components and compatibility according to the following assistant and guide effects:

(1) the monarch components mainly play a role in nutrition conditioning aiming at skin and subcutaneous tissues around eyes so as to maintain the health of the tissues around the eyes and prevent the degeneration of dermal elastic fibers;

(2) under the sustainable health state around the eyes, the minister component increases the water-fat emulsion on the surface of the skin, improves the hydration capability of the horny layer, and is matched with the monarch component to moisturize and remove wrinkles;

(3) the assistant components have slow release effect on monarch and minister components and maintain the long-acting moisturizing plain weave function;

(4) the components of the 'make' type play roles in blending, emulsifying, buffering, corrosion prevention and the like;

finally, the components are determined and reasonably divided into an agent A, an agent B and an agent C:

(1) the "monarch" component: new Zealand vanilla extract, coffee extract, hydrolyzed soybean polypeptide, heparin sodium, L-histidine, allantoin, recombinant human fibroblast 8a, caprylic/capric triglyceride, bisabolol, cetyl N-palmitoyl hydroxyproline, campesterol, nicotinamide;

(2) minister components: white chinlon oil, acetylated sodium hyaluronate, glycerol, sodium polyglutamate, dipeptide diaminobutyryl benzylamide diacetate, butanediol, acetyl hexapeptide-8 and squalane;

(3) the "adjuvant" component: cyclodextrin, p-hydroxyacetophenone;

(4) the "make" class of ingredients: disodium hydrogen phosphate, sodium dihydrogen phosphate, disodium EDTA, stearic acid, sucrose polystearate, hydrogenated polyisobutene, glyceryl stearate citrate, glyceryl stearate, PEG-100 stearate, cetearyl alcohol, cyclopentadimethylsiloxane, dimethicone crosspolymer, hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, acrylic acid/C10-30 alkanol acrylate crosspolymer, tromethamine, phenoxyethanol, hexyldecanol, ethylhexylglycerol.

The moisturizing and wrinkle-removing eye cream disclosed by the invention has the following beneficial effects:

(1) the skin-nourishing and activating cream is reasonably compatible according to the screening components of monarch, minister, assistant and guide, contains various plant extracts and cell nutrients, and comprises components of brassinosteroids, hydrolyzed soybean polypeptide, p-hydroxyacetophenone, coffee extract, squalane, cetostearyl alcohol, allantoin, recombinant human fibroblast 8a (rhFGF8a), bisabolol, meadowfoam seed oil, vanilla extract, L-histidine, nicotinamide and the like which are used for nourishing and activating skin cells and resisting oxidation;

(2) the rhFGF8a can obviously improve the expression level of Cx43 and strengthen the function of a cell connecting channel, thereby improving the absorption of nutrient substances and the excretion of metabolites of skin cells in both structural and functional aspects, the vitality of the epithelial cells is improved under the nutrition-enhanced microenvironment, and the application of the rhFGF8a can improve the endogenous nutrition of the skin, activate the epithelial function, enhance the skin texture, prevent the skin from aging and relieve the wrinkle formation;

(3) the compatible heparin sodium has the functions of increasing the vascular permeability of the skin and improving local vascular circulation; the combination of acetylated sodium hyaluronate, hexyldecanol, glycerin, butanediol, ethylhexylglycerin and sodium polyglutamate enhances the hydration capability of the cuticle without astringency by virtue of the super-strong moisturizing capability of the combination, and improves the skin compactness;

(4) the skin-care product is assisted by an emulsion stabilizer and a film-forming agent such as hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer, acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer, hydrogenated polyisobutene and the like to protect the skin, is matched with sucrose polystearate and caprylic/capric triglyceride to increase the water-fat emulsion on the surface of the skin, fully moisturizes the skin without greasiness, and is matched with dipeptide diaminobutyryl benzylamide diacetate and acetyl hexapeptide-8 to condition the skin and remove wrinkles.

Therefore, the moisturizing and wrinkle-removing eye cream disclosed by the invention can effectively repair skin around eyes and remove fine wrinkles and dry wrinkles around the eyes, and is safe, mild and non-irritant in a formula.

In the formulation of the present invention, recombinant human fibroblast 8a (rhFGF8a) was added, and the efficacy of this component will now be further explained.

The effect of rhFGF8a on human normal fibroblasts (HS68) was determined using CCK-8:

HS68 cells were digested, counted, plated in 96-well plates, and seeded at 1X 10 cells/well⁴Placing the cells at 37 deg.C and 5% CO₂Culturing in an incubator, and performing administration treatment after the cell density reaches 70-80%. The experiments were divided into three groups: blank group, control group, experimental group. Blank group only contains 1640 culture medium, 1% FBS, no HS68 cells and rhFGF8a, and CCK-8 solution is added for determination; the control group contained 1640 medium, 1% FBS, HS68 cells, and no rhFGF8a, with CCK-8 added for the assay; the experimental group contained 1640 medium, 1% FBS, HS68 cells, rhFGF8a, plus CCK-8 was measured. In the experimental group, rhFGF8a was added at 3.1ng/mL, 15.5ng/mL, 62ng/mL, 310ng/mL, 625ng/mL, and 1250ng/mL, respectively, CCK-8 was added after 24 hours of treatment, and after 1 hour of incubation, the absorbance at a wavelength of 450nm (reference wavelength of 650nm) was measured with a microplate reader and converted into growth rate, and the results are shown in Table 1 and FIG. 1.

Wherein, a blank group A is set_bControl group A_cExperimental group A_eThe calculation formula for converting the measured absorbance at a wavelength of 450nm (reference wavelength of 650nm) into the cell viability for each concentration group of rhFGF8a with the cell growth rate of the control group as 100% is as follows:

growth rate of cells (A)_e-A_b)/(A_c-A_b)*100％

After conversion of data to growth rate, analysis was performed using GraphPad Prism software, and data calculated as mean ± sd were analyzed, and each experimental group was subjected to pairwise comparison-t-test with the control group, and differences between test groups-F-test, P < 0.05(, P <0.01 (, P) was very significant, P <0.001 (, P) was very significant, and P < 0.0001(, P) was super-significant, which was statistically significant.

Table 1 effect of different concentrations of rhFGF8a on HS68 cell growth rate (

％)

F test is firstly carried out between A and F groups, and F is 6.954 and P is less than 0.001, which shows that the tissues have very significant difference. And then the groups B to F and the control group A are subjected to pairwise comparison t test, and the test result shows that when the concentration of the rhFGF8a is 15.5 ng/mL-310 ng/mL, the significant difference P is more than 0.05 compared with the control group, which indicates that the influence of the concentration interval on the growth of HS68 cells is not statistically significant. And the result of t test carried out on rhFGF8a at a concentration of 625 ng/mL-1250 ng/mL compared with the control group shows that P is less than 0.05, wherein the result of comparison of the experimental group with rhFGF8a at a concentration of 1250ng/mL compared with the control group shows that P is less than 0.001, and the difference is very significant compared with the control group. From the results of statistical analysis, it is found that when the concentration of rhFGF8a is 625 ng/mL-1250 ng/mL, the growth rate of HS68 cells is obviously promoted. As known to those skilled in the art, the activation of human normal fibroblasts (HS68) can increase the growth rate and enhance the ability of the cells to synthesize and secrete collagen and elastic fibers, thereby improving the firmness of the skin and reducing wrinkles.

Drawings

FIG. 1 is a statistical graph of the growth of HS68 cells by rhFGF8a at different concentrations (t test);

FIG. 2 is a graph comparing changes in canthus wrinkles before and after the administration of the product of the present invention to a subject, wherein (a) is before administration and (b) is after administration.

Detailed Description

In order to further explain the technical solution of the present invention, the present invention is explained in detail by the following specific examples.

and (2) agent B: 2.95-3.05 parts of caprylic/capric triglyceride, 0.15-0.25 part of N-palmitoyl hydroxyproline cetyl ester, 0.15-0.25 part of rape sterol, 0.15-0.25 part of hexyldecanol, 0.15-0.25 part of bisabolol, 0.15-0.25 part of stearic acid, 2.95-3.05 parts of white pond flower seed oil, 0.15-0.25 part of cyclopenta dimethyl siloxane, 0.75-0.85 part of sucrose polystearate, 0.75-0.85 part of hydrogenated polyisobutene, 0.2-0.3 part of glycerol stearate, 0.15-0.25 part of polydimethylsiloxane cross-linked polymer, 4.95-5.05 parts of squalane, and 0.55-0.65 part of acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer;

and (3) agent D: 1.45-1.55 parts of glycerol, 0.0001 part of heparin sodium, 0.5-0.6 part of L-histidine, 0.45-0.55 part of allantoin, 0.0000001-0.0000002 part of rhFGF8, 4.95-5.05 parts of hydrolyzed soybean polypeptide, 0.95-1.05 part of nicotinamide, 1.35-1.45 parts of glycerol stearate citrate, 0.95-10.05 parts of acetyl hexapeptide, 0.45-0.55 part of dipeptide diaminobutyryl benzylamide diacetate, 0.35-0.45 part of p-hydroxyacetophenone, 0.2-0.3 part of phenoxyethanol, 0.2-0.3 part of ethylhexyl glycerol, 0.2-0.3 part of PEG-100 stearate, 0.75-0.85 part of cetearyl alcohol and 1.95-2.05 part of butanediol.

step 1, adding the components of the agent A into a first mixing tank according to a formula ratio, stirring and dissolving at room temperature, and adjusting the pH to 5.5-6.5 by using citric acid-sodium citrate;

Example 1

a, an agent: 0.91g of disodium hydrogen phosphate, 7.09g of sodium dihydrogen phosphate, 0.4g of EDTA disodium, 3.4g of tromethamine and 1147.03g of deionized water;

and (B) an agent: 60g of caprylic/capric triglyceride, 4g of N-palmitoyl hydroxyproline cetyl ester, 4g of campesterol, 4g of hexyldecanol, 4g of bisabolol, 4g of stearic acid, 60g of meadowfoam seed oil, 5g of cyclopentadimethylsiloxane, 16g of sucrose polystearate, 16g of hydrogenated polyisobutene, 5g of glyceryl stearate, 4g of polydimethylsiloxane cross-linked polymer, 100g of squalane, and 12g of acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer;

c, agent C: 0.01g of vanilla extract, 20g of coffee extract, 4g of acetylated sodium hyaluronate, 4g of polyglutamic acid sodium, 20g of cyclodextrin and 8g of hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer;

and (3) agent D: 30g of glycerol, 2mg of heparin sodium, 11.16g of L-histidine, 10g of allantoin, 0.004mg of rhFGF8a 0.004, 100g of hydrolyzed soybean polypeptide, 20g of nicotinamide, 28g of glycerol stearate citrate, 10g of acetyl hexapeptide-8200 g of dipeptide diaminobutyryl benzylamide diacetate, 8g of p-hydroxyacetophenone, 5g of phenoxyethanol, 5g of ethylhexyl glycerol, 5g of PEG-100 stearate, 16g of cetearyl alcohol and 40g of butanediol.

step 1, adding the components of the agent A into a first mixing tank according to a formula ratio, stirring and dissolving at room temperature, and adjusting the pH value to 6.5 by using citric acid-sodium citrate;

step 2, adding the components of the agent B into a second mixing tank according to the formula proportion, heating to 85 ℃ under stirring, and keeping for 15 min;

step 3, adding the components of the agent C into a third mixing tank according to the formula proportion, then adding 126g of the agent A dissolved in the step 1, and heating to 65 ℃ under stirring;

step 4, adding the mixture of the agent A and the agent C formed in the step 3 into a second mixing tank to form a mixture of the agent A, the agent C and the agent B, continuing stirring, cooling to 65 ℃, and keeping for 20 min;

step 5, adding the components of the agent D into a fourth mixing tank according to the formula proportion, then adding 1021g of the agent A dissolved in the step 1, and heating to 40 ℃ under stirring;

step 6, pumping the mixture of the agent A, the agent C and the agent B at 65 ℃ in the step 4 into a homogenizer, homogenizing for 8min at 3600 r/min, pumping the mixture into a fourth mixing tank under stirring, mixing the mixture with the mixture of the agent A and the agent D, and continuously stirring for 15min at 40 ℃;

and 7, finally, pumping all the mixture in the fourth mixing tank at the temperature of 40 ℃ in the step 6 into a homogenizer, homogenizing for 10min at 3600 r/min, cooling to 37 ℃, aging for 24h, canning and subpackaging to obtain the moisturizing and wrinkle-removing eye cream.

Example 2

an agent A: 4.55g of disodium hydrogen phosphate, 35.46g of sodium dihydrogen phosphate, 2g of EDTA disodium, 17g of tromethamine and 5736.16g of deionized water;

and (2) agent B: 300g of caprylic/capric triglyceride, 20g of N-palmitoyl hydroxyproline cetyl ester, 20g of rape sterol, 20g of hexyldecanol, 20g of bisabolol, 20g of stearic acid, 300g of meadowfoam seed oil, 20g of cyclopentadimethylsiloxane, 80g of sucrose polystearate, 80g of hydrogenated polyisobutene, 25g of glycerol stearate, 20g of polydimethylsiloxane cross-linked polymer, 500g of squalane, and 60g of acrylic acid (ester)/C10-30 alkanol acrylate cross-linked polymer;

c, agent C: 0.02g of vanilla extract, 100g of coffee extract, 20g of acetylated sodium hyaluronate, 20g of polyglutamic acid sodium, 100g of cyclodextrin and 40g of hydroxyethyl acrylate/sodium acryloyldimethyl taurate copolymer;

and (3) agent D: 150g of glycerol, 10mg of heparin sodium, 55.8g of L-histidine, 50g of allantoin, 0.02mg of rhFGF8a 0.02, 500g of hydrolyzed soybean polypeptide, 100g of nicotinamide, 140g of glycerol stearate citrate, 81000 g of acetyl hexapeptide, 50g of dipeptide diaminobutyryl benzylamide diacetate, 40g of p-hydroxyacetophenone, 25g of phenoxyethanol, 25g of ethylhexyl glycerol, 25g of PEG-100 stearate, 80g of cetearyl alcohol and 200g of butanediol.

step 2, adding the components of the agent B into a second mixing tank according to the formula proportion, heating to 85 ℃ under stirring, and keeping for 20 min;

step 3, adding the components of the agent C into a third mixing tank according to the formula proportion, then adding 630g of the agent A dissolved in the step 1, and heating to 65 ℃ under stirring;

step 4, adding the mixture of the agent A and the agent C formed in the step 3 into a second mixing tank to form a mixture of the agent A, the agent C and the agent B, continuing stirring, cooling to 65 ℃, and keeping for 15 min;

step 5, adding the components of the agent D into a fourth mixing tank according to the formula proportion, then adding 5105g of the agent A dissolved in the step 1, and heating to 40 ℃ under stirring;

step 6, pumping the mixture of the agent A, the agent C and the agent B at 65 ℃ in the step 4 into a homogenizer, homogenizing for 10min at 6000 r/min, pumping the mixture into a fourth mixing tank under stirring, mixing the mixture with the mixture of the agent A and the agent D, and continuously stirring for 5min at 40 ℃;

and 7, finally pumping all the mixture in the fourth mixing tank at the temperature of 40 ℃ in the step 6 into a homogenizer, homogenizing for 15min at 6000 r/min, cooling to 37 ℃, aging for 24h, canning and subpackaging to obtain the moisturizing and wrinkle-removing eye cream.

Application example

18 subjects (female, age 25-45 years) were recruited for 2 weeks using the finished product prepared in example 2. The moisture content of the stratum corneum around the eyes of all the subjects before and after use was measured using a gpsk barrier tester (seoul GPOWER corporation, korea), and the average value of the moisture content of the stratum corneum on both sides of each subject was recorded. Statistical examination of the data from the front and back groups showed that the water content of the stratum corneum around the eyes was significantly increased after 2 weeks using the finished product prepared in example 2, and was statistically different (P <0.01), as shown in table 2. And as shown in fig. 2, the subject's canthus wrinkles were significantly reduced.

Table 2 comparison of the water content (%) of stratum corneum of subjects before and after use: (

±s)

Front side	Rear end
		50.41±5.58	56.91±4.65*

The above embodiments and drawings are not intended to limit the form and style of the present invention, and any suitable changes or modifications thereof by those skilled in the art should be considered as not departing from the scope of the present invention.

Claims

1. The moisturizing and wrinkle-removing eye cream is characterized in that: the composite material comprises the following raw materials in parts by weight:

2. Preparing a moisturizing and wrinkle-removing eye cream according to claim 1, characterized in that: the preparation method of the moisturizing and wrinkle-removing eye cream comprises the following steps: